Agilent Technologies, Inc. (NYSE:A) Shares Sold by Truist Financial Corp

Truist Financial Corp cut its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 3.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 33,091 shares of the medical research company’s stock after selling 1,141 shares during the period. Truist Financial Corp’s holdings in Agilent Technologies were worth $4,601,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the business. MV Capital Management Inc. grew its holdings in shares of Agilent Technologies by 120.7% during the fourth quarter. MV Capital Management Inc. now owns 192 shares of the medical research company’s stock valued at $27,000 after buying an additional 105 shares during the last quarter. OFI Invest Asset Management purchased a new stake in shares of Agilent Technologies during the third quarter valued at $25,000. Baystate Wealth Management LLC grew its holdings in shares of Agilent Technologies by 107.3% during the fourth quarter. Baystate Wealth Management LLC now owns 257 shares of the medical research company’s stock valued at $36,000 after buying an additional 133 shares during the last quarter. Turtle Creek Wealth Advisors LLC purchased a new stake in shares of Agilent Technologies during the fourth quarter valued at $39,000. Finally, Rosenberg Matthew Hamilton grew its holdings in shares of Agilent Technologies by 51.1% during the fourth quarter. Rosenberg Matthew Hamilton now owns 284 shares of the medical research company’s stock valued at $39,000 after buying an additional 96 shares during the last quarter. 87.42% of the stock is owned by institutional investors and hedge funds.

Agilent Technologies Stock Performance

NYSE:A opened at $139.45 on Monday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.04 and a current ratio of 2.68. The stock has a market capitalization of $40.87 billion, a P/E ratio of 33.20, a PEG ratio of 4.22 and a beta of 1.13. The company has a 50 day moving average price of $142.07 and a 200 day moving average price of $131.79. Agilent Technologies, Inc. has a fifty-two week low of $96.80 and a fifty-two week high of $151.58.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Tuesday, February 27th. The medical research company reported $1.29 EPS for the quarter, beating the consensus estimate of $1.22 by $0.07. Agilent Technologies had a net margin of 18.35% and a return on equity of 27.09%. The company had revenue of $1.66 billion during the quarter, compared to analysts’ expectations of $1.59 billion. During the same quarter last year, the company posted $1.37 EPS. The firm’s revenue was down 5.5% compared to the same quarter last year. Equities research analysts forecast that Agilent Technologies, Inc. will post 5.5 EPS for the current year.

Agilent Technologies Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 24th. Stockholders of record on Tuesday, April 2nd were issued a $0.236 dividend. The ex-dividend date was Monday, April 1st. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.68%. Agilent Technologies’s payout ratio is 22.38%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. UBS Group upped their price target on shares of Agilent Technologies from $130.00 to $155.00 and gave the company a “neutral” rating in a report on Wednesday, February 28th. Citigroup upped their price target on shares of Agilent Technologies from $130.00 to $145.00 and gave the company a “neutral” rating in a report on Wednesday, February 28th. Evercore ISI increased their target price on shares of Agilent Technologies from $132.00 to $145.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. Oppenheimer increased their target price on shares of Agilent Technologies from $67.00 to $90.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 26th. Finally, Barclays increased their target price on shares of Agilent Technologies from $125.00 to $135.00 and gave the stock an “underweight” rating in a research note on Wednesday, April 10th. One analyst has rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $141.29.

Insider Activity

In other news, Director Heidi Fields sold 1,658 shares of the firm’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $144.34, for a total value of $239,315.72. Following the sale, the director now directly owns 54,976 shares in the company, valued at approximately $7,935,235.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Heidi Fields sold 1,658 shares of Agilent Technologies stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $144.34, for a total transaction of $239,315.72. Following the sale, the director now directly owns 54,976 shares in the company, valued at approximately $7,935,235.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael R. Mcmullen sold 52,297 shares of Agilent Technologies stock in a transaction on Friday, March 8th. The stock was sold at an average price of $150.00, for a total transaction of $7,844,550.00. Following the sale, the chief executive officer now owns 253,909 shares in the company, valued at $38,086,350. The disclosure for this sale can be found here. In the last three months, insiders have sold 61,610 shares of company stock worth $9,220,333. 0.33% of the stock is currently owned by corporate insiders.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.